ЯЗАВА Син (JP),НИСИМУРА Тойо (JP),АСАО Такаюки (JP)
申请号：
RU2010140611/15
公开号：
RU2010140611A
申请日:
2009.03.04
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A chemotherapeutic agent against cancer, containing, in combination, a cholestanol derivative represented by the formula (1)! ! (where G is GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-), or its inclusion compound with cyclodextrin, and an anti-cancer agent. ! 2. A chemotherapeutic agent against cancer according to claim 1, where in the formula (1) G is GlcNAc-Gal- or GlcNAc-. ! 3. The cancer chemotherapeutic agent of claim 1, wherein the anticancer agent is one or more kinds of agents selected from the group consisting of an anticancer agent, which is taxane, an anticancer agent, which is a complex of platinum, a compound of pemetrexed and fluorouracil. ! 4. The chemotherapeutic agent for cancer according to claim 3, where the anticancer agent is one or more types of drugs selected from the group consisting of paclitaxel, docetaxel, alimta, 5-FU, cisplatin and oxaliplatin. ! 5. A chemotherapeutic agent against cancer according to any one of claims 1 to 4, which is a mixed agent. ! 6. A chemotherapeutic agent against cancer according to any one of claims 1 to 4, which is in the form of a kit comprising a drug containing a cholestanol derivative and a drug containing an anti-cancer agent. ! 7. The chemotherapeutic agent against cancer according to claim 6, wherein the drug containing the cholestanol derivative is a liposome composition. ! 8. The use, in combination, of a cholestanol derivative represented by the formula (1)! ! (where G is GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-), or its compounds including1. Химиотерапевтическое средство против рака, содержащее, в комбинации, производное холестанола, представленное формулой (1) ! ! (где G представляет собой GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- или GlcNAc-), или его соединение включения с циклодекстрином, и противораковое средство. ! 2. Химиотерапевтическое средство против рака по п.1, где в формуле (1) G представляет собой GlcNAc-Gal- или GlcNAc
